On April 14, 2026, Galera Therapeutics, Inc. announced a merger with Obsidian Therapeutics, where Galera will become a wholly owned subsidiary of Obsidian. Following the merger, equity holders are expected to own approximately 1.8% of the combined company, which values Galera at $13.8 million and Obsidian at $413.5 million.